A Randomized Controlled Trial of Pre-Operative Treatment With Ferrous Fumarate 300 mg Once Daily Versus Placebo in Newly Diagnoses Gynecologic Oncology Patients Who Are Primary Surgical Candidates.
The prevalence of anemia in gynecologic oncology new patients has been seen in previous
studies to be as high as 35-59%. this population includes women with several types of
gynecologic malignancies. Therefore, it is assumed that the origin of the anemia can be due
to anemia of chronic disease and iron deficiency anemia. No previous studies have looked at
the efficacy of oral iron supplementation with concurrent Vitamin C in women with newly
diagnosed gynecologic malignancies.
Hypothesis: In newly diagnosed gynecologic oncology patients who are surgical candidates
does treatment with 3-6 weeks of oral ferrous fumarate 300 mg once a day improve the mean
change in hemoglobin levels, from baseline to pre-operative, in comparison to placebo.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society